FOR IMMEDIATE RELEASE:

QPS Delaware Greatly Expands Translational Medicine Capabilities

New capacity will support large-scale, Phase III drug trials

(June 27, 2017; Newark, Delaware) – QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, is investing in additional technical personnel and laboratory capacity for translational medicine at its flagship Delaware Technology Park facility. This significant expansion will enable QPS Delaware to process the high sample volumes required for Phase III clinical drug trials.

Once complete, new hiring is projected to increase laboratory staff from 57 to 88. Most of these additions are to be technical personnel and will raise the number of analysis teams from seven to eleven. The relationship-building, one-client-one-team approach is a hallmark of QPS efficiency. A special working group to handle regulatory authorities’ rising demand for neutralizing antibody assays has also been added.

To accommodate the increase in technical operations, QPS has expanded the square footage devoted to immunobioanalysis and cell culture, as well as the protein mass spectrometry area.

“For a long time, clients have known us as the boutique CRO - a high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation,” says John L. Kolman, PhD, VP and Global Head of Translational Medicine at QPS. “Now we are in a position to follow through and support Phase III, even for very large studies.”
Translational Medicine is a growing, multidisciplinary science focused on speeding translation of experimental discoveries into effective diagnostic tools and therapies.

**About QPS Holdings, LLC**

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing quality services to pharmaceutical and biotechnology clients worldwide. QPS linearly integrated core competencies include: neuropharmacology, DMPK, liver research, toxicology, bioanalysis, translational medicine, and clinical research program management. QPS regional laboratories and testing facilities are located at company headquarters in Newark, DE; Springfield, MO; Fargo, ND; Hollywood, FL; South Miami, FL, USA; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; Barcelona, Spain; and Taipei, Taiwan.

For more information, visit qps.com

**Contact:**

Reinier Schwietert, PhD
VP of Global Marketing
Tel: +31 651148308
reinier.schwietert@qps.com